12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

AstraZeneca neurology, cardiovascular news

AstraZeneca disclosed in its 3Q13 earnings that it received a subpoena in September from the U.S. Attorney's Office in Boston, Mass., seeking documents related to the safety profile of the pharma's schizophrenia drug Seroquel...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >